Prognostic value of cyclin E expression in breast cancer: a meta-analysis
- 276 Downloads
Cyclin E is an important regulator of cell cycle progression. Various studies examined the relationship between cyclin E overexpression with the clinical outcome in patients with breast cancer but yielded conflicting results. Electronic databases updated to May 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between cyclin E overexpression and survival of patients with breast cancer. Survival data were aggregated and quantitatively analyzed. We conducted a final analysis of 7,759 patients from 23 eligible studies and evaluated the correlation between cyclin E overexpression and survival in patients with breast cancer. Combined hazard ratios suggested that cyclin E overexpression had an unfavorable impact on overall survival (OS) (hazard ratio (HR) = 1.30, 95 % confidence interval (CI), 1.12–1.49) and breast cancer-specific survival (BCSS) (HR = 1.48, 95 % CI, 1.03–1.93), but not disease-free survival (HR = 1.11; 95 % CI, 0.96–1.27) in patients with breast cancer. Significantly, risks were found among stage I–II breast cancer for (HR = 1.75; 95 % CI, 1.30–2.19). Cyclin E overexpression is associated with poor OS and BCSS in breast cancer.
KeywordsCyclin E Breast cancer Prognosis Disease-free survival Meta-analysis
This work was supported in part by the National Natural Science Foundation of China (81172501).
Conflicts of interest
- 31.Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res. 2006;12(21):6421–31.PubMedCrossRefGoogle Scholar
- 34.Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res. 2006;12(11 Pt 1):3319–28.PubMedCrossRefGoogle Scholar
- 39.Sgambato A, Camerini A, Collecchi P, Graziani C, Bevilacqua G, Capodanno A, et al. Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci. 2009;100(6):1026–33.PubMedCrossRefGoogle Scholar
- 40.Lemée F, Bergoglio V, Fernandez-Vidal A, Machado-Silva A, Pillaire MJ, Bieth A, et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A. 2010;107(30):13390–5.PubMedCrossRefGoogle Scholar